Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Finished Goods (2016 - 2018)

Historic Finished Goods for Anika Therapeutics (ANIK) over the last 8 years, with Q3 2018 value amounting to $4.6 million.

  • Anika Therapeutics' Finished Goods fell 2030.58% to $4.6 million in Q3 2018 from the same period last year, while for Sep 2018 it was $4.6 million, marking a year-over-year decrease of 2030.58%. This contributed to the annual value of $4.7 million for FY2017, which is 301.76% up from last year.
  • According to the latest figures from Q3 2018, Anika Therapeutics' Finished Goods is $4.6 million, which was down 2030.58% from $5.2 million recorded in Q2 2018.
  • In the past 5 years, Anika Therapeutics' Finished Goods registered a high of $6.8 million during Q1 2018, and its lowest value of $3.1 million during Q1 2015.
  • Its 5-year average for Finished Goods is $4.6 million, with a median of $4.6 million in 2018.
  • Per our database at Business Quant, Anika Therapeutics' Finished Goods surged by 14787.51% in 2014 and then crashed by 4193.27% in 2015.
  • Quarter analysis of 5 years shows Anika Therapeutics' Finished Goods stood at $3.2 million in 2014, then increased by 9.3% to $3.5 million in 2015, then grew by 29.64% to $4.5 million in 2016, then increased by 3.02% to $4.7 million in 2017, then dropped by 0.81% to $4.6 million in 2018.
  • Its Finished Goods was $4.6 million in Q3 2018, compared to $5.2 million in Q2 2018 and $6.8 million in Q1 2018.